What is Rhythm Pharmaceu's earnings per share (EPS)?

Rhythm Pharmaceu (RYTM) reported diluted earnings per share of $-3.11 for fiscal year 2025. This represents a 28.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rhythm Pharmaceu Financials

RYTM

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Rhythm Pharmaceu (RYTM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 46/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Rhythm Pharmaceu has an operating margin of -101.2%, meaning the company retains $-101 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -204.0% the prior year.

Growth

100

Rhythm Pharmaceu's revenue surged 45.8% year-over-year to $189.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Rhythm Pharmaceu carries a low D/E ratio of 0.73, meaning only $0.73 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 87/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.41, Rhythm Pharmaceu holds $4.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.

Cash Flow

While Rhythm Pharmaceu generated -$115.7M in operating cash flow, capex of $953K consumed most of it, leaving -$116.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Rhythm Pharmaceu generates a -141.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -1199.3% the prior year.

Piotroski F-Score Neutral

5/9

Rhythm Pharmaceu passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.59x

For every $1 of reported earnings, Rhythm Pharmaceu generates $0.59 in operating cash flow (-$115.7M OCF vs -$196.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-9.3x

Rhythm Pharmaceu earns $-9.3 in operating income for every $1 of interest expense (-$192.0M vs $20.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$189.8M

YoY+45.8%

Rhythm Pharmaceu generated $189.8M in revenue in fiscal year 2025. This represents an increase of 45.8% from the prior year.

EBITDA

-$191.5M

YoY+27.7%

Rhythm Pharmaceu's EBITDA was -$191.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.7% from the prior year.

Net Income

-$196.5M

YoY+24.6%

Rhythm Pharmaceu reported -$196.5M in net income in fiscal year 2025. This represents an increase of 24.6% from the prior year.

EPS (Diluted)

$-3.11

YoY+28.3%

Rhythm Pharmaceu earned $-3.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 28.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$116.6M

YoY-2.4%

Rhythm Pharmaceu generated -$116.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 2.4% from the prior year.

Cash & Debt

$54.3M

YoY-39.1%

5Y CAGR-11.6%

10Y CAGR+4.5%

Rhythm Pharmaceu held $54.3M in cash against $100.9M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

67M

YoY+7.7%

5Y CAGR+8.7%

Rhythm Pharmaceu had 67M shares outstanding in fiscal year 2025. This represents an increase of 7.7% from the prior year.

Margins & Returns

Gross Margin

89.7%

YoY+0.0pp

Rhythm Pharmaceu's gross margin was 89.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.0 percentage points from the prior year.

Operating Margin

-101.2%

YoY+102.8pp

Rhythm Pharmaceu's operating margin was -101.2% in fiscal year 2025, reflecting core business profitability. This is up 102.8 percentage points from the prior year.

Net Margin

-103.6%

YoY+96.7pp

Rhythm Pharmaceu's net profit margin was -103.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 96.7 percentage points from the prior year.

Return on Equity

-141.3%

YoY+1058.0pp

5Y CAGR-60.9pp

Rhythm Pharmaceu's ROE was -141.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1058.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$167.3M

YoY-29.7%

5Y CAGR+13.1%

10Y CAGR+37.1%

Rhythm Pharmaceu invested $167.3M in research and development in fiscal year 2025. This represents a decrease of 29.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$953K

5Y CAGR+34.8%

10Y CAGR+49.6%

Rhythm Pharmaceu invested $953K in capex in fiscal year 2025, funding long-term assets and infrastructure.

RYTM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$189.8M+45.8%	$130.1M+68.1%	$77.4M+227.6%	$23.6M+649.5%	$3.2M	$0
Cost of Revenue	$19.5M+45.8%	$13.4M+43.7%	$9.3M+336.1%	$2.1M+256.1%	$599K	N/A
Gross Profit	$170.3M+45.8%	$116.8M+71.4%	$68.1M+216.8%	$21.5M+741.7%	$2.6M	N/A
R&D Expenses	$167.3M-29.7%	$238.0M+76.3%	$135.0M+24.2%	$108.6M+4.3%	$104.1M+15.1%	$90.5M
SG&A Expenses	$194.9M+35.1%	$144.3M+22.8%	$117.5M+27.7%	$92.0M+34.4%	$68.5M+48.5%	$46.1M
Operating Income	-$192.0M+27.7%	-$265.5M-44.0%	-$184.4M-2.9%	-$179.2M-5.3%	-$170.1M-24.5%	-$136.6M
Interest Expense	$20.6M-0.1%	$20.6M+48.3%	$13.9M+167.1%	$5.2M	N/A	N/A
Income Tax	$497K+43.6%	$346K-38.7%	$564K	N/A	N/A	N/A
Net Income	-$196.5M+24.6%	-$260.6M-41.1%	-$184.7M-2.0%	-$181.1M-160.2%	-$69.6M+48.0%	-$134.0M
EPS (Diluted)	$-3.11+28.3%	$-4.34-35.6%	$-3.20+7.8%	$-3.47-147.9%	$-1.40+53.9%	$-3.04

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$57.3M+11.6%	$51.3M+5.8%	$48.5M+48.3%	$32.7M-21.8%	$41.8M+25.8%	$33.3M+14.4%	$29.1M+12.0%	$26.0M
Cost of Revenue	$4.8M-12.7%	$5.5M-0.8%	$5.5M+51.9%	$3.6M-3.6%	$3.8M-1.1%	$3.8M+29.9%	$2.9M+5.0%	$2.8M
Gross Profit	$52.5M+14.5%	$45.8M+6.6%	$43.0M+47.8%	$29.1M-23.6%	$38.0M+29.3%	$29.4M+12.6%	$26.1M+12.8%	$23.2M
R&D Expenses	$42.0M-8.7%	$46.0M+8.8%	$42.3M+14.4%	$37.0M-10.2%	$41.2M+8.5%	$37.9M+25.6%	$30.2M-76.5%	$128.7M
SG&A Expenses	$57.5M+9.6%	$52.4M+14.1%	$45.9M+17.6%	$39.1M+2.5%	$38.1M+7.8%	$35.4M-2.9%	$36.4M+5.9%	$34.4M
Operating Income	-$47.1M+10.6%	-$52.7M-16.2%	-$45.3M+3.6%	-$47.0M-13.9%	-$41.3M+6.0%	-$43.9M-8.4%	-$40.5M+71.1%	-$139.9M
Interest Expense	$4.6M-2.7%	$4.7M-18.5%	$5.8M+7.5%	$5.4M-9.9%	$6.0M+14.5%	$5.2M+13.9%	$4.6M-3.2%	$4.8M
Income Tax	-$31K-127.9%	$111K-67.1%	$337K+321.3%	$80K+189.9%	-$89K+74.1%	-$344K-171.8%	$479K+59.7%	$300K
Net Income	-$47.5M+10.2%	-$52.9M-13.4%	-$46.6M+5.8%	-$49.5M-14.2%	-$43.3M+0.7%	-$43.6M-35.3%	-$32.3M+77.2%	-$141.4M
EPS (Diluted)	N/A	$-0.82-9.3%	$-0.75+7.4%	$-0.81	N/A	$-0.73-32.7%	$-0.55+76.6%	$-2.35

RYTM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$480.2M+22.4%	$392.3M+17.9%	$332.7M-13.0%	$382.5M+16.1%	$329.5M+76.1%	$187.1M
Current Assets	$466.9M+24.8%	$374.2M+21.4%	$308.3M-13.0%	$354.2M+14.9%	$308.4M+69.8%	$181.7M
Cash & Equivalents	$54.3M-39.1%	$89.1M+48.4%	$60.1M-52.9%	$127.7M+115.5%	$59.2M-41.3%	$100.9M
Inventory	$25.8M+37.4%	$18.7M+117.3%	$8.6M+195.6%	$2.9M+2527.9%	$111K	N/A
Accounts Receivable	$26.1M+40.9%	$18.5M+24.5%	$14.9M+138.9%	$6.2M+507.2%	$1.0M	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$341.1M-7.9%	$370.5M+127.3%	$163.0M+37.9%	$118.2M+160.6%	$45.4M+120.8%	$20.5M
Current Liabilities	$105.9M-8.3%	$115.5M+109.3%	$55.2M+38.7%	$39.8M-8.3%	$43.4M+141.3%	$18.0M
Long-Term Debt	$100.9M-6.8%	$108.3M+2.0%	$106.1M	N/A	N/A	N/A
Total Equity	$139.1M+540.0%	$21.7M-87.2%	$169.8M-35.8%	$264.3M-7.0%	$284.2M+70.6%	$166.5M
Retained Earnings	-$1.4B-17.0%	-$1.2B-29.1%	-$894.7M-26.0%	-$710.1M-34.2%	-$528.9M-15.2%	-$459.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$480.2M-5.3%	$506.9M+36.0%	$372.7M-3.6%	$386.7M-1.4%	$392.3M+7.9%	$363.6M-4.8%	$381.8M+47.6%	$258.7M
Current Assets	$466.9M-5.6%	$494.8M+37.2%	$360.7M-2.3%	$369.3M-1.3%	$374.2M+9.9%	$340.3M-4.8%	$357.4M+51.6%	$235.8M
Cash & Equivalents	$54.3M+4.3%	$52.1M-61.6%	$135.6M+27.8%	$106.1M+19.0%	$89.1M+87.6%	$47.5M-70.6%	$161.7M+202.6%	$53.4M
Inventory	$25.8M+16.5%	$22.1M+17.1%	$18.9M-2.3%	$19.3M+3.1%	$18.7M+34.9%	$13.9M+15.8%	$12.0M+41.0%	$8.5M
Accounts Receivable	$26.1M-21.0%	$33.0M+26.5%	$26.1M+46.5%	$17.8M-3.7%	$18.5M-4.1%	$19.3M+9.7%	$17.6M+19.8%	$14.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$341.1M-4.7%	$358.1M-6.9%	$384.6M+4.6%	$367.7M-0.8%	$370.5M+5.2%	$352.4M+2.9%	$342.5M+73.8%	$197.1M
Current Liabilities	$105.9M+1.6%	$104.3M-19.5%	$129.5M+15.8%	$111.8M-3.2%	$115.5M+18.4%	$97.6M+78.4%	$54.7M+1.0%	$54.2M
Long-Term Debt	$100.9M-2.4%	$103.4M-2.5%	$106.0M-1.8%	$107.9M-0.3%	$108.3M	N/A	N/A	N/A
Total Equity	$139.1M-6.6%	$148.8M+1349.7%	-$11.9M-162.8%	$18.9M-12.8%	$21.7M+93.7%	$11.2M-71.5%	$39.3M-36.1%	$61.6M
Retained Earnings	-$1.4B-3.6%	-$1.3B-4.2%	-$1.3B-3.9%	-$1.2B-4.3%	-$1.2B-3.9%	-$1.1B-4.1%	-$1.1B-3.1%	-$1.0B

RYTM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$115.7M-1.6%	-$113.9M+16.4%	-$136.2M+21.5%	-$173.4M-18.8%	-$146.0M-19.7%	-$122.0M
Capital Expenditures	$953K	$0-100.0%	$47K-83.3%	$281K-35.3%	$434K+102.8%	$214K
Free Cash Flow	-$116.6M-2.4%	-$113.9M+16.4%	-$136.2M+21.6%	-$173.7M-18.6%	-$146.4M-19.8%	-$122.2M
Investing Cash Flow	-$137.2M-184.7%	-$48.2M-750.4%	-$5.7M-120.2%	$28.0M+145.1%	-$62.2M-139.2%	$158.5M
Financing Cash Flow	$218.0M+14.0%	$191.2M+157.2%	$74.4M-65.2%	$213.8M+28.4%	$166.5M+8186.8%	$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$25.4M+4.6%	-$26.6M-14.2%	-$23.3M+42.2%	-$40.4M-114.1%	-$18.8M+25.3%	-$25.2M+13.3%	-$29.1M+28.6%	-$40.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$30.3M+112.3%	-$246.3M-555.9%	$54.0M+117.8%	$24.8M+17.3%	$21.2M+123.3%	-$90.8M-960.7%	-$8.6M-128.5%	$30.1M
Financing Cash Flow	-$2.9M-101.6%	$189.3M+21393.7%	-$889K-102.7%	$32.5M-15.2%	$38.3M+1438.0%	$2.5M-98.3%	$146.2M+3345.2%	$4.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RYTM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	89.7%0.0pp	89.7%+1.7pp	88.0%-3.0pp	91.0%+10.0pp	81.0%	N/A
Operating Margin	-101.2%+102.8pp	-204.0%+34.1pp	-238.1%+519.8pp	-757.9%+4633.9pp	-5391.9%	N/A
Net Margin	-103.6%+96.7pp	-200.3%+38.3pp	-238.5%+527.7pp	-766.2%+1440.9pp	-2207.1%	N/A
Return on Equity	-141.3%+1058.0pp	-1199.3%-1090.5pp	-108.8%-40.3pp	-68.5%-44.0pp	-24.5%+56.0pp	-80.5%
Return on Assets	-40.9%+25.5pp	-66.4%-10.9pp	-55.5%-8.2pp	-47.3%-26.2pp	-21.1%+50.5pp	-71.6%
Current Ratio	4.41+1.2	3.24-2.3	5.58-3.3	8.90+1.8	7.10-3.0	10.10
Debt-to-Equity	0.73-4.3	4.98+4.4	0.63+0.2	0.45+0.3	0.16+0.0	0.12
FCF Margin	-61.5%+26.0pp	-87.5%+88.4pp	-175.9%+559.0pp	-734.9%+3908.0pp	-4642.9%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	91.6%+2.3pp	89.3%+0.7pp	88.6%-0.3pp	88.8%-2.1pp	91.0%+2.5pp	88.5%-1.4pp	89.9%+0.7pp	89.2%
Operating Margin	-82.2%+20.4pp	-102.6%-9.3pp	-93.4%+50.3pp	-143.7%-45.1pp	-98.6%+33.4pp	-132.0%+7.2pp	-139.2%+399.5pp	-538.7%
Net Margin	-83.0%+20.2pp	-103.1%-7.0pp	-96.1%+55.2pp	-151.3%-47.8pp	-103.6%+27.7pp	-131.3%-20.3pp	-110.9%+433.5pp	-544.4%
Return on Equity	-34.2%+1.4pp	-35.5%	N/A	-261.2%-61.8pp	-199.4%+189.7pp	-389.1%-307.1pp	-82.0%+147.6pp	-229.6%
Return on Assets	-9.9%+0.6pp	-10.4%+2.1pp	-12.5%+0.3pp	-12.8%-1.8pp	-11.1%+0.9pp	-12.0%-3.5pp	-8.5%+46.2pp	-54.7%
Current Ratio	4.41-0.3	4.75+2.0	2.79-0.5	3.30+0.1	3.24-0.2	3.49-3.0	6.53+2.2	4.35
Debt-to-Equity	0.73+0.0	0.69+9.6	-8.90-14.6	5.70+0.7	4.98-26.4	31.42+22.7	8.71+5.5	3.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Abivax S.A. ABVX

$8.0B

Legend Biotech Corp LEGN

$3.2B

Cytokinetics Inc CYTK

$7.8B

Axsome Therapeut AXSM

$8.2B

Nuvalent, Inc. NUVL

$7.6B

Frequently Asked Questions

What is Rhythm Pharmaceu's annual revenue?

Rhythm Pharmaceu (RYTM) reported $189.8M in total revenue for fiscal year 2025. This represents a 45.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rhythm Pharmaceu's revenue growing?

Rhythm Pharmaceu (RYTM) revenue grew by 45.8% year-over-year, from $130.1M to $189.8M in fiscal year 2025.

Is Rhythm Pharmaceu profitable?

No, Rhythm Pharmaceu (RYTM) reported a net income of -$196.5M in fiscal year 2025, with a net profit margin of -103.6%.

What is Rhythm Pharmaceu's EBITDA?

Rhythm Pharmaceu (RYTM) had EBITDA of -$191.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Rhythm Pharmaceu have?

As of fiscal year 2025, Rhythm Pharmaceu (RYTM) had $54.3M in cash and equivalents against $100.9M in long-term debt.

What is Rhythm Pharmaceu's gross margin?

Rhythm Pharmaceu (RYTM) had a gross margin of 89.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Rhythm Pharmaceu's operating margin?

Rhythm Pharmaceu (RYTM) had an operating margin of -101.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Rhythm Pharmaceu's net profit margin?

Rhythm Pharmaceu (RYTM) had a net profit margin of -103.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Rhythm Pharmaceu's return on equity (ROE)?

Rhythm Pharmaceu (RYTM) has a return on equity of -141.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rhythm Pharmaceu's free cash flow?

Rhythm Pharmaceu (RYTM) generated -$116.6M in free cash flow during fiscal year 2025. This represents a -2.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Rhythm Pharmaceu's operating cash flow?

Rhythm Pharmaceu (RYTM) generated -$115.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rhythm Pharmaceu's total assets?

Rhythm Pharmaceu (RYTM) had $480.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Rhythm Pharmaceu's capital expenditures?

Rhythm Pharmaceu (RYTM) invested $953K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Rhythm Pharmaceu spend on research and development?

Rhythm Pharmaceu (RYTM) invested $167.3M in research and development during fiscal year 2025.

How many shares does Rhythm Pharmaceu have outstanding?

Rhythm Pharmaceu (RYTM) had 67M shares outstanding as of fiscal year 2025.

What is Rhythm Pharmaceu's current ratio?

Rhythm Pharmaceu (RYTM) had a current ratio of 4.41 as of fiscal year 2025, which is generally considered healthy.

What is Rhythm Pharmaceu's debt-to-equity ratio?

Rhythm Pharmaceu (RYTM) had a debt-to-equity ratio of 0.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rhythm Pharmaceu's return on assets (ROA)?

Rhythm Pharmaceu (RYTM) had a return on assets of -40.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rhythm Pharmaceu's cash runway?

Based on fiscal year 2025 data, Rhythm Pharmaceu (RYTM) had $54.3M in cash against an annual operating cash burn of $115.7M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rhythm Pharmaceu's Piotroski F-Score?

Rhythm Pharmaceu (RYTM) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rhythm Pharmaceu's earnings high quality?

Rhythm Pharmaceu (RYTM) has an earnings quality ratio of 0.59x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rhythm Pharmaceu cover its interest payments?

Rhythm Pharmaceu (RYTM) has an interest coverage ratio of -9.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Rhythm Pharmaceu?

Rhythm Pharmaceu (RYTM) scores 46 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.